Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Srivatsan Raghavan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5374-9918; OpenAlex author ID A5027546748; NIH RePORTER profile ID 12344779. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
1
Labs led
1
Collaborators
104
Papers, trials and grants by year

2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 6 papers · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers, 1 grant

Papers 18

  1. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  2. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  3. HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Co-author DOI 10.1038/s41467-025-60129-1↗
  4. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Co-author DOI 10.1126/science.adk3487↗
  5. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  6. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  7. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  8. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Co-author DOI 10.1016/j.xcrm.2023.101007↗
  9. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. Co-author DOI 10.1053/j.gastro.2023.05.038↗
  10. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  11. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  12. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  13. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  14. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  15. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗
  16. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  17. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1090↗
  18. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗

Grants 1

  1. Regulation and targeting of tumor cell states and plasticity in pancreatic cancer K08CA260442↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew J. Aguirre · 15 shared papers, 2018–2026 · strength 1.97
  2. Brian Matthew Wolpin · 14 shared papers, 2018–2026 · strength 1.83
  3. James M. Cleary · 12 shared papers, 2021–2026 · strength 1.69
  4. Kimberly J. Perez · 9 shared papers, 2021–2026 · strength 1.25
  5. Douglas Adam Rubinson · 9 shared papers, 2021–2026 · strength 1.23
  6. Harshabad Singh · 8 shared papers, 2021–2026 · strength 1.16
  7. Jonathan Andrew Nowak · 8 shared papers, 2021–2026 · strength 1.12
  8. Kimmie Ng · 6 shared papers, 2021–2026 · strength 0.85
  9. Brandon M. Huffman · 5 shared papers, 2021–2026 · strength 0.75
  10. Geoffrey Ira Shapiro · 5 shared papers, 2021–2026 · strength 0.64
  11. Rishi Surana · 4 shared papers, 2023–2026 · strength 0.61
  12. Matthew B.B. Yurgelun · 4 shared papers, 2023–2026 · strength 0.59
  13. Thomas Adam Abrams · 4 shared papers, 2023–2026 · strength 0.59
  14. Andressa Dias Costa · 4 shared papers, 2021–2026 · strength 0.53
  15. ANDREA C Enzinger · 3 shared papers, 2025–2026 · strength 0.52
  16. Hannah L. Williams · 4 shared papers, 2021–2025 · strength 0.50
  17. Leah H. Biller · 3 shared papers, 2023–2026 · strength 0.47
  18. Alan D. D’Andrea · 3 shared papers, 2021–2026 · strength 0.44
  19. Stephanie K. Dougan · 3 shared papers, 2021–2024 · strength 0.42
  20. William C. Hahn · 4 shared papers, 2018–2023 · strength 0.41
  21. Chen Yuan · 3 shared papers, 2023–2024 · strength 0.39
  22. Mary Linton B. Peters · 2 shared papers, 2025–2026 · strength 0.34
  23. Andrea J. Bullock · 2 shared papers, 2025–2026 · strength 0.34
  24. Tyler Jacks · 3 shared papers, 2018–2025 · strength 0.33
  25. Thomas E. Clancy · 3 shared papers, 2021–2023 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.